Table 2. Lung lactate and pyruvate production over the 15 min treatment periods (μmol ·15 min⁻¹·gram⁻¹ dry lung) in Protocol 1 studies.

Measurements were made in pulmonary venous effluent samples of a subset of lungs in Table 1. The values are means ± SE. Statistical analysis was carried out as described in Table 1. Means with the same letter designation are in the same group and not significantly different (p>0.05); means with different letter designations are in different groups and significantly different from each other (p<0.05).

Treatment	n	Lactate	Pyruvate	Lactate + Pyruvate
Vehicle Control	4	12.36 ± 1.64 ^c	0.88 ± 0.11 ^d	13.24 ± 1.66 ^c
Rotenone	4	38.62 ± 3.14 ^a	0.87 ± 0.14 ^d	39.49 ± 3.12 ^a
Rotenone + CoQ₁	3	24.64 ± 1.96 ^b	2.58 ± 0.20 ^a	27.23 ± 1.92 ^b
CoQ₁	4	14.77 ± 2.02 ^c	2.12 ± 0.18 ^a,b	16.90 ± 2.08 ^c
Rotenone + CoQ₁ + Dicumarol	4	34.31 ± 0.81 ^a	1.70 ± 0.26 ^b,c	36.01 ± 0.97 ^a
Rotenone + CoQ₁ + Antimycin A	4	34.63 ± 2.22 ^a	1.42 ± 0.06 ^c	36.05 ± 2.19 ^a

Table 2. Lung lactate and pyruvate production over the 15 min treatment periods (μmol ·15 min−1·gram−1 dry lung) in Protocol 1 studies.

Table 2. Lung lactate and pyruvate production over the 15 min treatment periods (μmol ·15 min⁻¹·gram⁻¹ dry lung) in Protocol 1 studies.